Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article : Merck KGaA, Bayer AG
Stocks mentioned in the article
ChangeLast1st jan.
BAYER -0.60% 99 Delayed Quote.-4.81%
MERCK KGAA 0.02% 82.02 Delayed Quote.-8.61%
SANOFI -0.49% 65.28 Real-time Quote.-9.14%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
04/21SANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
04/20SANOFI : Advent International enters into exclusive negotiations to acquire Zent..
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
04/18SANOFI : in talks with Advent to sell its European generics unit for €1.9bn
04/17SANOFI : CFO Contamine to retire later this year
More news
News from SeekingAlpha
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 633 M
Net income 2018 4 940 M
Debt 2018 14 433 M
Yield 2018 4,71%
P/E ratio 2018 16,06
P/E ratio 2019 14,21
EV / Sales 2018 2,75x
EV / Sales 2019 2,58x
Capitalization 81 998 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 21%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.14%100 746
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890